par Bui, Le ;Menchi, Elena ;Hennia, Ismaël ;Amighi, Karim ;Wauthoz, Nathalie
Référence Drug Delivery to the Lungs (34: 2023/12/06 - 2023/12/08: Edinburgh, Scottland), The Aerosol Society Drug Delivery to the Lungs 34, Vol. 37, page (1941-2711)
Publication Publié, 2024
Poster de conférence
Résumé : Introduction. Dry powder inhalers (DPIs) in the treatment of non-communicable chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) are one of the most widely used devices used by the patients. However, the appropriate use or choice of inhalable medications can be challenging for patients and healthcare professionals. Poor adherence due to high frequency of administration, errors in inhalation technique and/or use of DPIs may cause the loss of asthma or COPD control. In the present study, we aim to develop a dry powder for inhalation (DPI) formulation based on controlled release of budesonide (BUD) using a lipid matrix based on hydrogenated castor oil (HCO) and tocopherol polyethylene glycol 1000 succinate (TPGS) to decrease the administration frequency. Methods. BUD formulations were produced using the spray-drying particle engineering technique. The aerodynamic properties were assessed using the Next Generation Impactor (NGI) according to the European Pharmacopeia. The release properties of BUD were assessed using a paddle apparatus with a Fast Screening Impactor cassette for dissolution. Results. The formulations showed optimal aerodynamic properties with a fine particle fraction related to the nominal dose (FPFn) comprised between 52.5% to 53.5% as well as drug releases that decreased depending on the content of HCO (20 (% w:v) or 95 (% w:v)) and TPGS (5% (w:w) of the excipients). Conclusion. Our results suggest that the content of the lipid matrix in HCO and TPGS is responsible of the extended drug release in PBS – 0.02% Tween20 (w:v) and fine particle ratio (FPF).

Documents en relation

DI-fusion